This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
== Reduction of food packaging == Reduced packaging and sustainable packaging are becoming more frequent, although excessive overpackaging is still common. The motivations can be government regulations, consumer pressure, retailer pressure, and cost control. Reduced packaging often saves packaging costs. In the UK, a Local Government Association survey produced by the British Market Research Bureau compared a range of outlets to buy 29 common food items, and found that small, local retailers and market traders "produced less packaging and more that could be recycled than the larger supermarkets."
==== Air tray drying ==== Tempeh can be dried via the air tray drying method. Cubes of tempeh placed on steel, mesh bottom trays are dried by the circulating hot air dryer. After the product is finished, they can be cut into 2.5-centimetre (1-inch) squares at 90 °C (200 °F) for 90 to 120 minutes in order to reduce moisture content to 2–4%. When placed in moisture proof Pliofilm bags, the tempeh has a shelf life of several months at room temperature. Although this is a convenient method that produces a shelf stable product without requirement of refrigeration, the process of hot air drying can cause a significant loss of nutritional content such as the soluble solids and nitrogen protein content.
In Japan, labeling guidelines introduced in 2007 recommend that the designation Wagyu be used only for beef from cattle documented as one of the four breeds or specified crosses between them and confirmed as having been born and raised in Japan. Beginning in the 1970s, cattle and genetic material exported from Japan formed the basis of Wagyu herds in the United States and Australia. Breed associations in both countries maintain their own herdbooks and DNA-based parentage-verification systems, registering cattle according to their documented pedigree and proportion of Wagyu ancestry.
==== South Korea ==== South Korea's funeral arrangements have drastically changed in the course of only two decades according to Chang-Won Park. Park states that around the 1980s at home funeral ceremonies were the general norm, straying away from anywhere that was not a family home. Dying close to home, with friends and family, was considered a 'good death', while dying away from home was considered a 'bad death'. This gradually changed as the upper and middle class started holding funerals in the mortuaries of hospitals. This posed an issue for hospitals because of the rapid increase in funerals being held and maxing occupancy. This resolved when a law was passed to allow the civilian population to hold funerals in the mortuaries of hospitals. The lower class then followed suit, copying the newly set traditions of the upper classes. With this change, the practice of cremation became viewed more as an alternative to traditional burials. Cremation was first introduced by Buddhism, but was banned in 1470. It was not until the Japanese colonization period that cremation was reintroduced in 1945 and the ban later lifted. It took until 1998 for cremation to rapidly grow in popularity.
Sources: en.wikipedia.org
== A == AACTG – acquired immunity – acquired immunodeficiency syndrome (AIDS) – ACT UP/Golden Gate – active immunity – acupuncture – acute HIV infection – Acute HIV Infection and Early Diseases Research Program (AIEDRP) – ADAP – ADC – adenopathy – adherence – adjuvant – administration – Adult AIDS Clinical Trials Group (AACTG) – adverse drug reaction – aerosolized – AETC – agammaglobulinemia – Agency for Healthcare Research and Quality (AHRQ) – AHRQ – AIDS – AIDS Arms – AIDS dementia complex (ADC) – AIDS Drug Assistance Programs (ADAP) – AIDS education and training centers (AETC) – AIDS orphan – AIDS research advisory committee (ARAC) – AIDS service organization (ASO) – The AIDS Show – AIDS Vaccine 200 – AIDS Vaccine Advocacy Coalition – AIDS wasting syndrome – AIDS-related cancer – AIDS-related complex (ARC) – alkaline phosphatase – alopecia – alpha interferon (INFa) – alternative medicine – alveolar – amebiasis – amino acids – anaphylactic shock – anemia – anergy – angiogenesis – angiomatosis – anorexia – antenatal – antibiotic – antibodies – antibody-dependent cell-mediated cytotoxicity (ADCC) – antibody-mediated immunity – antifungal medication – antigen – antigen presentation – antigen-presenting cell (APC) – antineoplastic – antiprotozoal – antiretroviral drugs – antisense drugs – antitoxins – Antiviral drug – aphasia – aphthous ulcer – apoptosis – approved drugs – ARC – Armenicum – ART – arthralgia – ASO – aspergillosis – assembly and budding – asymptomatic – ataxia – attenuated – autoantibody – autoimmunization – autoinoculation – autologous – avascular necrosis (AVN) – AVN
== Society and culture == It is manufactured by GlaxoSmithKline (GSK), Mylan Pharmaceuticals, Cipla, Dr. Reddy's Laboratories and Sun Pharmaceutical. The discovery of the drug's utility in restless legs syndrome has been used as an example of successful drug repurposing.
2,3-diDHB dehydrogenase is a tetramer protein with dimension 65x69x43 Å. It has a crystallographic 222 symmetry, which exhibited for other members of short-chain oxireductase (SCOR) family of enzymes. The length of each monomer is 248 residues and the weight of the protein is 24647 Da. Each monomer consists of 7 beta-pleated sheets and 6 alpha helices. Although the structure of the binding protein is not clearly defined, it was proposed that the binding pocket is made out of Leu83, Met85, Arg138, Gly140, Met141, Ser176, Met181, Gln182 and Leu185. It was also speculated that Arg138 is a likely subunit that interacts with the carboxyl group of 2,3-diDHB. Since there was a strong indication of oxidation at C3 position, Ser176 and Gln182 interact with the C2-hydroxyl group in order for the stereo-selective reaction to occur.
== Further reading == Gogarten, J Peter; Elena Hilario (2006). "Inteins, introns, and homing endonucleases: recent revelations about the life cycle of parasitic genetic elements". BMC Evol Biol. 6 (1): 94. doi:10.1186/1471-2148-6-94. ISSN 1471-2148. PMC 1654191. PMID 17101053.
According to this equation, maximum resolution is reached when the electrophoretic and electroosmotic mobilities are similar in magnitude and opposite in sign. In addition, it can be seen that high resolution requires lower velocity and, correspondingly, increased analysis time. Besides diffusion and Joule heating (discussed above), factors that may decrease the resolution in capillary electrophoresis from the theoretical limits in the above equation include, but are not limited to, the finite widths of the injection plug and detection window; interactions between the analyte and the capillary wall; instrumental non-idealities such as a slight difference in height of the fluid reservoirs leading to siphoning; irregularities in the electric field due to, e.g., imperfectly cut capillary ends; depletion of buffering capacity in the reservoirs; and electrodispersion (when an analyte has higher conductivity than the background electrolyte). Identifying and minimizing the numerous sources of band broadening is key to successful method development in capillary electrophoresis, with the objective of approaching as close as possible to the ideal of diffusion-limited resolution.
Sources: en.wikipedia.org
== Ubiquitin ligase families == Humans have an estimated 500-1000 E3 ligases, which impart substrate specificity onto the E1 and E2. The E3 ligases are classified into four families: HECT, RING-finger, U-box, and PHD-finger. The RING-finger E3 ligases are the largest family and contain ligases such as the anaphase-promoting complex (APC) and the SCF complex (Skp1-Cullin-F-box protein complex). SCF complexes consist of four proteins: Rbx1, Cul1, Skp1, which are invariant among SCF complexes, and an F-box protein, which varies. Around 70 human F-box proteins have been identified. F-box proteins contain an F-box, which binds the rest of the SCF complex, and a substrate binding domain, which gives the E3 its substrate specificity.
{\displaystyle {\begin{aligned}{\frac {\mathbf {D} m}{\mathbf {Dt} }}&={\iiint \limits _{V}}\left({{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )}\right)dV\\{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot {\mathbf {u} })&={\frac {\partial \rho }{\partial t}}+({\nabla \rho })\cdot {\mathbf {u} }+{\rho }(\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot ({\rho \mathbf {u} })=0\end{aligned}}}
=== Argentina === The president of the Justicialist Party (and former Argentine president), Cristina Fernández de Kirchner, criticized the strikes, labelling Maduro's capture as "kidnapping" and stated that Trump "crossed the line again".
In the fields of medicine, biotechnology, and pharmacology, drug discovery is the process by which new drugs are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products, or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compound libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Even more recently, scientists have been able to understand the shape of biological molecules at the atomic level and to use that knowledge to design (see drug design) drug candidates. Modern drug discovery involves the identification of screening hits, medicinal chemistry, and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.